Icatibant: Difference between revisions
Kurtucla05 (talk | contribs) |
|||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*30mg subcutaneous | ===[[Hereditary angioedema]]=== | ||
*30mg subcutaneous x 1 | |||
**May repeat q6h if inadequate response/symptoms recur | |||
*Max 90mg/24 hours | *Max 90mg/24 hours | ||
Revision as of 20:35, 8 August 2015
General
- Type: Bradykinin receptor antagonist
- Dosage Forms: 30mg
- Routes of Administration: Subcutaneous
- Common Trade Names: Firazyr
Adult Dosing
Hereditary angioedema
- 30mg subcutaneous x 1
- May repeat q6h if inadequate response/symptoms recur
- Max 90mg/24 hours
Pediatric Dosing
not available (8/2015)
Special Populations
- Pregnancy Rating: C
- Lactation risk: safety unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Caution if acute MI
- Caution if unstable angina
- Caution if recent stroke
Common
Pharmacology
- Half-life: 1.4h
- Metabolism: Proteolytic degradation
- Excretion: Urine 10% unchanged
- Mechanism of Action: selectively antagonizes bradykinin B2 receptor
Comments
- NEJM article 1/2015 randomized 27 people with ACEi induced angioedema to icatibant vs std therapy (Prednisone 500mg + Clemastine 2mg) looking at time to resolution.
RESULTS- significantly shorter (8 hrs vs 27.1 hrs) in icatibant group.
- Cost according to Goodrx= $9,000/dose (on 8/7/2015)